MARLBOROUGH, Mass., May 3, 2017 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced the schedule of key data presentations, including two late-breaking clinical trials, that will be featured at the 38th Annual Scientific Sessions of the Heart Rhythm Society in Chicago on May 10-13.
Notably, the post-market approval data collected on the Subcutaneous Implantable Defibrillator (S-ICD) System in the U.S., as well as ‘real-world’ data regarding the efficacy of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, will be presented during late-breaking clinical trial sessions on May 11 and May 12, respectively. Other scheduled presentations and abstracts underscore the following:
- extended follow-up on pacing performance with the ACUITY™ X4 Quadripolar Left Ventricular leads;
- additional pre-clinical evidence supporting the company’s modular therapy approach and communications compatibility between its EMPOWER™ Modular Pacing System and the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System;
- pre-clinical data showcasing new software that further expands the diagnostic capabilities of the Rhythmia HDx™ Mapping System.
“We are pleased to present growing evidence that reinforces the safety and efficacy of technologies across our cardiovascular portfolio,” said Kenneth Stein, M.D., senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific. “Further, we look forward to results gathered by independent research within the clinical community that embrace our cardiac mapping technology and evaluate the performance of its differentiating features.”
Source: PR Newswire
